Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

Breast. 2023 Feb:67:8-13. doi: 10.1016/j.breast.2022.12.004. Epub 2022 Dec 15.

Abstract

The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients. This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone.

Keywords: Adjuvant therapy; Capecitabine; Network meta-analysis; Prognosis; Resected triple negative breast cancer.

Publication types

  • Meta-Analysis

MeSH terms

  • Anthracyclines / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Humans
  • Network Meta-Analysis
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / surgery

Substances

  • taxane
  • Anthracyclines